The "POWERFUL" multicenter, retrospective, and prospective study investigated the effectiveness of pomalidomide plus low-dose dexamethasone (POM/LoDex) therapy in relapsed/refractory multiple myeloma in routine care in Greece. Ninety-nine eligible adult patients treated with POM/LoDex according to the approved label after having received ≥2 prior therapies, including lenalidomide and bortezomib, were consecutively enrolled between 16 November 2017 and 21 February 2019 in 18 hematology departments. Fifty patients (50.5%) started POM/LoDex as third-line treatment. During the treatment period (median: 8.3 months; range: 0.3-47.6 months), the median POM dose was 4 mg/day, and 31.3% of the patients received additional antimyeloma agents. The overall response rate was 32.3%. During a median follow-up period of 13.8 months (Kaplan-Meier estimate), the median progression-free survival (PFS) was 10.5 months (95% CI: 7.4-14.4). The PFS was not significantly different between patients receiving POM/LoDex in the third versus later line of therapy, nor between patients receiving concomitant antimyeloma therapy versus POM/LoDEx doublet. During the prospective safety data collection period (median: 7.6 months) among patients with prospective follow-up (N = 75), POM-related adverse event incidence rate was 42.7% (serious: 18.7%; grade ≥ 3 hematological POM-related adverse events: 8.0%). Only neutropenia (13.3%) was reported at a frequency ≥10%. In conclusion, in this real-world study, POM/LoDex displayed a long PFS with no new safety signals emerging.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038613 | PMC |
| http://dx.doi.org/10.3390/jcm10071509 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of Anti-CD38 Monoclonal Antibodies for Relapsed or Refractory Multiple Myeloma in Stem Cell Transplant-Ineligible Patients Aged over 65 Years: A Propensity Score-Matched Study.
Hematol Rep
November 2024
Department of Hematology, St. Mary's Hospital, Kurume 830-8543, Japan.
Background: The development of newer agents, including anti-CD38 monoclonal antibodies (mAbs), has significantly improved overall survival (OS) in patients with relapsed or refractory multiple myeloma (RRMM). However, the treatment of older patients with RRMM who are transplant-ineligible remains challenging.
Methods: We retrospectively evaluated OS in 78 transplant-ineligible patients with RRMM who were aged ≥ 65 years and treated at our institution between February 2012 and November 2023.
Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial.
Ann Hematol
March 2024
Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, #8, the South Road of Workers Stadium of Chaoyang District, Beijing, 100020, China.
This multicenter, open-label, single-arm trial (ClinicalTrials.gov, NCT05236621) was conducted to confirm the efficacy and safety of generic pomalidomide plus dexamethasone in Chinese patients with relapsed or refractory multiple myeloma (RRMM). Total 79 eligible RRMM patients were planned to be included.
View Article and Find Full Text PDFNovel Pharmacological Treatment Options of Steroid-Refractory Graft-versus-Host Disease.
Adv Hematol
December 2023
The Christ Hospital Network, Cincinnati, Ohio, USA.
Article Synopsis
- Graft-versus-host disease (GVHD) is a serious complication of hematopoietic stem cell transplants, with current steroid treatments being ineffective in 30-50% of cases, leading to high mortality rates in steroid-refractory GVHD (SR-GVHD).
- This review analyzes new therapeutic options for SR-GVHD, emphasizing experimental drugs like ruxolitinib, monoclonal antibodies, and other agents that show promise but require more research on their safety and effectiveness.
- While some agents demonstrate potential for improving treatment outcomes in chronic GVHD, further rigorous trials are needed to confirm their efficacy on a larger scale.
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
Lancet Haematol
October 2023
University Medical Center of Hamburg-Eppendorf, Hamburg, Germany.
Article Synopsis
- Multiple myeloma is an incurable cancer with limited treatment options for patients whose disease has returned after previous therapies; belantamab mafodotin has shown promise in early studies for these patients.
- The DREAMM-3 phase 3 study involved 325 participants worldwide who were randomized to receive either belantamab mafodotin or a combination of pomalidomide and dexamethasone, with the main goal of evaluating progression-free survival.
- The study is ongoing, with patients recruited between April 2020 and April 2022, and it aims to determine the safety and efficacy of belantamab mafodotin compared to traditional treatments by September 2022.
Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial.
BMC Cancer
July 2022
Department of Hematology, Peking University People's Hospital and Peking University Institute of Hematology, Beijing, China.
Background: Pomalidomide in combination with dexamethasone has demonstrated positive results in patients with relapsed or refractory multiple myeloma (RRMM), but no data are available in China. We conducted a multicenter, single-arm trial to examine the efficacy and safety of bioequivalent generic pomalidomide plus low-dose dexamethasone in Chinese RRMM patients.
Methods: Adult (≥ 18 years of age) RRMM patients who progressed after at least two previous treatments, including bortezomib and lenalidomide, were eligible.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!